R&D News | pharmaphorum

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Fulcrum repurposes failed GSK drug for rare disease

GSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked up by biotech Fulcrum Therapeutics, who want to repurpose the drug to treat the ra

News

Second death in gene therapy trial prompts investigation

A second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – a potential blockbuster for this rare disease – has prompte

News

Pfizer/Lilly non-opioid pain drug shows more positive result...

Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the dr

News

Antibody suppresses HIV for four months

A new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the virus for up to four months after patients stopped taking antiretroviral medicines.<

Digital

AI firm Insitro signs Gilead as first pharma partner with NA...

Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner.

News

Drugs could mimic gut bacteria benefits to treat diabetes

It may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat diseases such as type II diabetes, a new study has found.

Fulcrum repurposes failed GSK drug for rare disease

Second death in gene therapy trial prompts investigation

Pfizer/Lilly non-opioid pain drug shows more positive result...

Antibody suppresses HIV for four months

AI firm Insitro signs Gilead as first pharma partner with NA...

Drugs could mimic gut bacteria benefits to treat diabetes

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks